

WHO Drug Information

Volume 9, 1995: Index

A

ACE inhibitors, (2) 62
 renal failure, (1) 16
 Acetylsalicylic acid, (1) 36, (2) 62
 colorectal cancer, (4) 210
 Acinetobacter, hospital-acquired infection, (1) 25
 AIDS update, (4) 196
 Albendazole, (3) 135
 Aminophylline, (2) 54
 Aminosalicylates, (3) 158
 Amphotericin, (4) 215
 Antibiotic resistance, (1) 15
 Antibiotics in eclipse, (1) 1
 Antibiotics, (3) 127
 Antimicrobial susceptibility tests, (3) 158
 Antiretroviral therapy, (4) 198
 Antistreptococcal vaccine, (1) 22
 Azathioprine, (2) 68

B

Bacterial resistance, (1) 1
 Bednets, malaria, (3) 151
 Bifidobacterium, (1) 14
 Budesonide, (2) 68

C

Captopril, (1) 16, (2) 63
 Cephalosporins, (3) 142
 Chloroquine, (1) 39
 Chlorpropamide, (2) 61
 Ciclosporin, (2) 68
 Clomifene, (3) 159
 Clozapine, (1) 34
 Community-acquired infections, (2) 43
 Contraceptives, spermicide, (3) 163
 Corticosteroids, (2) 68
 Coumarin, (3) 159
 Cyproterone acetate, (1) 30, (3) 162
 Cysticidal drugs, (3) 135

D

Deferiprone, (2) 57
 Defining the scope of the licensing
 procedure, (2) 77
 Dexamethasone, (3) 135
 Diabetes, non-insulin therapy, (2) 60
 Didanosine, (4) 196
 Diethylcarbazine, (3) 132
 Diethylene glycol, (3) 127
 Ditiocarb sodium, (4) 205
 Diuretics, (2) 70
 DMPA, breast cancer, (1) 20
 Drug resistance, (2) 44

E

Emergence of newly-resistant strains, (1) 2
 Enalapril, (1) 17
 Erythromycin, (2) 75, (3) 143
 Essential drugs, (2) 79
 model list, (4) 235

F

Fake drugs, (3) 127
 Fluconazole, cryptococcal meningitis, (1) 23

G

Gene therapy, HIV, (4) 204
 Glibenclamide, (2) 61
 Guidelines on defining the scope, (2) 77

H

Hepatitis B vaccination, (3) 146
 Herbal preparations, (3) 148
 HIV test, oral fluid, (1) 33
 HIV treatment, (4) 193
 HIV vaccine development, (4) 202
 Homoeopathy, (3) 149
 Hydroxyurea and sickle-cell disease, (1) 26

I

Ibuprofen, (1) 37
 Indometacin, (1) 38
 Influenza, vaccine, (3) 138
 Informed consent in emergencies, (3) 154
 INN lists, (2) 81, (3) 165, (4) 235
 Inosine pranobex, (4) 205
 Insulin strength, (3) 163
 Integrase inhibitors, (4) 197
 Interferon alfa, (4) 205
 Interferon gamma, (4) 205
 Interleukin-2, (4) 205
 Iron chelation, beta-thalassaemia, (1) 28
 Iron-containing drugs, (3) 159
 Ivermectin, (3) 132, (3) 144

K

Kanamycin, (3) 142

L

Labelling, paediatric, (1) 32
 Lamivudine, (4) 196
 Licence variations, (2) 73
 Licensing procedure, (2) 77
 Lymphatic filariasis, (3) 132

M

Macrolide antibiotics, (3) 162
Magnesium sulfate, (2) 63, (3) 130
Malaria, (3) 151
 vaccine, (3) 135
Measles vaccine, vitamin A, (3) 138
Medical records, (3) 150
Medication errors, (3) 157
Mercaptopurine, (2) 68
Metformin, (1) 30, (2) 61
Methotrexate, (1) 41, (2) 54, (2) 68
Multidrug resistance, (1) 3
Myocardial infarction, (2) 62

N

Naftidrofuryl infusion, (4) 222
Naltrexone, (1) 33
Natural medicines, (3) 147
Natural remedies, (3) 155
Nifedipine, (4) 220
Nucleoside analogues, (4) 196, 212
Nucleic acid vaccines, (4) 205

O

Oral contraceptives, breast cancer, (1) 18
 thromboembolism, (4) 221
Orphan drugs, (2) 72
OTC advertising, (1) 10

P

Paediatric labelling, (1) 32
Pancreatic enzyme factor, (2) 58
Pancreatins, (1) 30
Penicillamine, (1) 40
Penicillin, AIDS, (2) 66
Penicillin, neurosyphilis, (2) 66
Pimozide, (1) 32
Pneumococcal drug-resistance, (4) 217
Poliomyelitis vaccine, (2) 59
Polypharmacy, (4) 217
Povidone-iodine, (3) 142
Praziquantel, (3) 135
Prednisolone, (1) 42, (2) 68
Product information, (2) 79
Protease inhibitors, (4) 197

Q

Quality assurance, (3) 128
Quinacrine, (1) 33
Quinolones, (3) 160

R

Reporting requirements, (2) 75
Resistant strains, (1) 3
Rheumatoid arthritis, (1) 35
Rotavirus vaccine, (1) 14

S

Saccharomyces boulardii, (1) 15
Selegiline, (3) 160
Silver nitrate, (3) 142
Simvastatin, (3) 161
Socially-responsive development of
 medicines, II (1) 1, III (2) 43
Spectinomycin, (3) 142
Starting materials, pharmaceuticals, (3) 156
Stavudine, (4) 196
Streptokinase, (2) 62
Sulfamethoxazole/trimethoprim, (3) 161
Sulfasalazine, (1) 40, (2) 68

T

Tacrolimus, (3) 161
Tamoxifen, (2) 72
Tetracycline 1%, (3) 142
Thiacetazone, (2) 55
Tocolytics, (3) 160
Traditional eye medicines, (3) 152
Trimethoprim/sulfamethoxazole, (3) 161
Triple-drug HIV regimens, (4) 197
Tropical disease research, (3) 164

U

Update on AIDS, (4) 196
Use of essential drugs, (2) 79

V

Vaccine development, HIV, (4) 203
 new horizons, (2) 47
Vaccine, antistreptococcal, (1) 22
 hepatitis B, (3) 145
 influenza, (3) 138
 malaria, (3) 135
 measles, vitamin A, (3) 139
 poliomyelitis, (2) 59
 rotavirus, (1) 14
 nucleic acid, (4) 205
Vigabatrin, (2) 75
Vitamin A, (3) 141
 measles vaccine, (3) 139

W

Warfarin, (3) 162
WHO Model List, (4) 223

Z

Zalcitabine, (4) 196
Zidovudine, (4) 193, 196